The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.

The present invention relates to a compound represented by the formula (I) or a salt thereof.

##STR00001##

wherein each symbol is as described in the specification, or a salt thereof.

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.

The present invention relates to a compound represented by the formula (I) or a salt thereof.

##STR00001##

wherein each symbol is as described in the specification, or a salt thereof.

The present invention relates to the development of polypeptides useful for the treatment of diseases associated with amyloid deposits, and more specifically for the treatment of Alzheimer's disease. The invention also relates to compositions comprising the developed polypeptides and to a method for the identification of compounds useful for the treatment of diseases associated with the formation of amyloid deposits.

The present invention relates to the development of polypeptides useful for the treatment of diseases associated with amyloid deposits, and more specifically for the treatment of Alzheimer's disease. The invention also relates to compositions comprising the developed polypeptides and to a method for the identification of compounds useful for the treatment of diseases associated with the formation of amyloid deposits.

The present invention relates to a use for the purpose of preventing, alleviating, or treating bipolar disorder by administering a pharmaceutical composition comprising a carbamate compound of the following chemical formula 1.

The present invention relates to a compound used as an RET kinase inhibitor and an application thereof. The compound has a structure represented by formula F, has a good inhibitory ability for RET kinase, and has relatively good pharmacodynamic and pharmacokinetic performance, and lower toxic side effects.

##STR00001##

The present invention relates to a compound used as an RET kinase inhibitor and an application thereof. The compound has a structure represented by formula F, has a good inhibitory ability for RET kinase, and has relatively good pharmacodynamic and pharmacokinetic performance, and lower toxic side effects.

##STR00001##

A wipe has a substrate, a treatment solution impregnated into the substrate, the treatment solution including an antifungal agent, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution is essentially free of alcohol. A treatment solution, has an antifungal agent, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution has an alcohol content of 6 wt % or below of the total solution.

A wipe has a substrate, a treatment solution impregnated into the substrate, the treatment solution including an antifungal agent, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution is essentially free of alcohol. A treatment solution, has an antifungal agent, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution has an alcohol content of 6 wt % or below of the total solution.

Described herein are compositions and methods for the increasing the quantity of lipids secreted from meibomian glands. Such compositions and methods are useful for the treatment of meibomian gland dysfunction and disorders resulting therefrom.